Carrie Brodmerkel
IGM Biosciences (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Psoriasis: Treatment and Pathogenesis, Rheumatoid Arthritis Research and Therapies, Gene expression and cancer classification, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial(2013)792 cited
- → Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease(2017)772 cited
- → Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis(2011)395 cited
- → Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis(2012)307 cited
- → Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis(2014)298 cited
- → Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials(2014)293 cited
- → A functional genomics predictive network model identifies regulators of inflammatory bowel disease(2017)266 cited
- → Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity(2022)221 cited
- → Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis(2014)210 cited
- → Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum(2015)188 cited